Secondary analysis of economic data: A review of cost-benefit studies of neonatal screening for phenylketonuria

Journal of Epidemiology and Community Health

Volumn 53, Issue 3, 1999, Pages 179-186

  Lord, Joanne ^a   Thomason, Margaret J ^a   Littlejohns, Peter ^a   Chalmers, Ronald A ^a   Bain, Murray D ^a   Addison, G Michael ^b   Wilcox, A Hervey ^c   Seymour, Carol A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; HEALTH CARE COST; HUMAN; INCIDENCE; MEDICAL LITERATURE; METHODOLOGY; NEWBORN; NEWBORN SCREENING; PHENYLKETONURIA; PROFIT; RESIDENTIAL CARE; UNITED KINGDOM;

EID: 0033051830     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.53.3.179     Document Type: Article

References (43)

1. MRC Working Party on Phenylketonuria. Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. BMJ 1993;306:115-19.
2. MRC Working Party on Phenylketonuria. Recommendations on the dietary management of phenylketonuria. Arch Dis Child 1993;68:426-7.
3. Pollitt RJ, Green A, McCabe CJ, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess 1997;1.
4. Thomason MJ, Lord J, Bain MD, et al. A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. J Public Health Med 1998;20:331-43.
5. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care 1992;30:231-43.
6. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
7. Jefferson T, Mugford M, Gray A, et al. An exercise on the feasibility of carrying out secondary economic analysis. Health Econ 1996;5:155-65.
8. Koopmanschap MA, Rutten RFH. The impact of indirect costs on outcomes of health care programs. Health Econ 1994;3:385-93.
9. Smith I, Cook B, Beasley M. Review of neonatal screening programme for phenylketonuria. BMJ 1991;303:333-5.
10. Wright M. An evaluation of the cost benefit analysis approach. A case study: a CBA of the screening and treatment of PKU. [MSc Thesis]. Glasgow: University of Strathclyde, 1990.
11. Cockburn F, Clark BJ, Byrne A, et al. Maternal phenylketonuria - diet, dangers and dilemmas. International Paediatrics 1992;7:67-74.
12. Briggs A, Sculpher MJ, Buxton MJ. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994;3:95-104.
13. Cunningham GC. Two years of PKU testing in California. The role of the laboratory. Californian Medicine 1969;110: 11-16.
14. Bush JW, Chen MM, Patrick DL. Health status index in cost effectiveness: analysis of PKU program. In: Berg, ed. Health status indexes. New York: Hospital and Educational Trust, 1973:172-209.
15. Steiner KC, Smith HA. Application of cost-benefit analysis to a PKU screening program. Inquiry 1973;10:34-40.
16. Webb JF. PKU screening, is it worth it? Can Med Assoc J 1973;108:328-9.
17. Van Pelt A, Levy H. Cost-benefit analysis of newborn screening for metabolic disorders. N Engl J Med 1974;291: 1414-16.
18. Komrower GM, Sardharwalla IB, Fowler B, et al. The Manchester regional screening programme: a 10-year exercise in patient and family care. BMJ 1979;2:635-8.
19. Veale AMO. Screening for hereditary metabolic disorders. Screening for Phenylketonuria. In: Bickle H, Guthrie R, Hammersen G, eds. Neonatal screening for inborn errors of metabolism. New York: Springer-Verlag, 1980:7-18.
20. Alm J, Larsson A, Rosenqvist U. Health economic analysis of the Swedish neonatal metabolic screening programme: a method of optimizing routines. Med Decis Making 1982;2: 33-45.
21. Goss S. Cost-benefit analysis of the detection and treatment of phenylketonuria (PKU) in newly-born babies, in Belgium. Cahiers Economique de Bruxelles 1983;459-68.
22. Barden HS, Kessel R, Schuett VE. The costs and benefits of screening for PKU in Wisconsin. Soc Biol 1984;31:1-17.
23. Dhondt J-L, Farriaux J-P, Sailly J-C, et al. Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. J Inherit Metab Dis 1991;14:633-9.
24. Hisashige A. Health economic analysis of the neonatal screening program in Japan. Int J Technol Assess Health Care 1994;10:382-91.
25. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med 1992;116: 238-44.
26. Rutten-van Molken MP, van Doorslaer EK, Rutten FF. Economic appraisal of asthma and COPD care: a literature review 1980-91. Soc Sci Med 1992;35:161-75.
27. Evers SMAA, Van Wijk AS, Ament AJHA. Economic evaluation of mental health care interventions. A review. Health Econ 1997;6:161-77.
28. Jefferson T, Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 1994;3: 25-37.
29. Mason J, Drummond MF. Reporting guidelines for economic studies. Health Econ 1995;4:85-94.
30. Briggs A, Sculpher MJ. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 1995;4:355-71.
31. Jacobs P, Bachynsky J. Costing methods in the Canadian literature on the economic evaluation of health care: A survey and assessment. Int J Technol Assess Health Care 1996;12: 721-34.
32. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-7.
33. Centre for Reviews and Dissemination. Making cost-effectiveness information accessible: the NHS economic evaluation database project. CRD guidance for reporting critical summaries of economic evaluations. CRD Report Number 6. York: NHS Centre for Reviews and Dissemination, University of York, 1996.
34. Alm J, Bodegard G, Larsson A, et al. Children with inborn errors of phenylalanine metabolism: prognosis and phenylalanine tolerance. Acta Paediatr Scand 1986;75:619-25.
35. Sweetman L. Newborn screening by tandem mass spectrometry (MS-MS). Clin Chem 1996;42:345-6.
36. Chace DH, Millington DS, Terada N, et al. Rapid diagnosis of phenylketonuria by quantitative analysis for pnenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 1993;39:66-71.
37. Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1.
38. Lubenow N, Diepenbrock F, Schickling H, et al. Phenylketonuria screening with a fluorometric microplate assay. Eur J Clin Chem Clin Biochem 1994;32:525-8.
39. Fisch R, Bilek OM, Bruhl HH. Causes of death of institutionalized phenylketonuric (PKU) patients - a national survev. Minn Med 1976;53:306-9.
40. Office for National Statistics. Annual abstract of statistics. London: The Stationery Office, 1997.
41. Netten A, Dennert J. Unit costs of health and social care 1996. Canterbury: PSSRU University of Kent, 1996.
42. Bennett N, Jarvis L, Rowlands O, et al. Living in Britain: Results from the 1994 General Household Survey. Office of Population Censuses and Surveys, Social Survey Division. London: HMSO, 1996.
43. Office for National Statistics. New Earnings Survey 1996. London: HMSO, 1996.